Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Avery Spitz"'
1
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study
Autor: Haiyi Cao, Mario A. Eisenberger, Michael T. Schweizer, Avery Spitz, Michael A. Carducci, Brandon Luber, Hao Wang, Emmanuel S. Antonarakis, Channing J. Paller, Samuel R. Denmeade, Rosa Nadal, D. Marc Rosen
Publikováno v: The Prostate. 76:1218-1226
BACKGROUND We have previously documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e., Bipolar Androgen Therapy; BAT). Because, an adaptive increase in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e49266db5341afc7e4f2aafec57062d
https://doi.org/10.1002/pros.23209
Zobrazit plný text záznamu
2
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study
Autor: Michael T, Schweizer, Hao, Wang, Brandon, Luber, Rosa, Nadal, Avery, Spitz, D Marc, Rosen, Haiyi, Cao, Emmanuel S, Antonarakis, Mario A, Eisenberger, Michael A, Carducci, Channing, Paller, Samuel R, Denmeade
Publikováno v: The Prostate. 76(13)
We have previously documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e., Bipolar Androgen Therapy; BAT). Because, an adaptive increase in androgen r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1be50ac17c51422d5f1f444320125736
https://pubmed.ncbi.nlm.nih.gov/27338150
Zobrazit plný text záznamu
3
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Autor: Haiyi Cao, Srinivasan Yegnasubramanian, Samuel R. Denmeade, Michael A. Carducci, A. Seun Ajiboye, Michael C. Haffner, Jun Luo, John T. Isaacs, Emmanuel S. Antonarakis, Michael T. Schweizer, Mario A. Eisenberger, Hao Wang, Avery Spitz
Publikováno v: Science Translational Medicine. 7
Targeting androgen receptor (AR) axis signaling by disrupting androgen-AR interactions remains the primary treatment for metastatic prostate cancer. Unfortunately, all men develop resistance to primary castrating therapy and secondary androgen depriv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db26fa0fc495649c44881659765d51a0
https://doi.org/10.1126/scitranslmed.3010563
Zobrazit plný text záznamu
4
Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC)
Autor: Samuel R. Denmeade, Hao Wang, Avery Spitz, Haiyi Cao, Michael T. Schweizer, Rosa Nadal, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael A. Carducci, Channing J. Paller, David Marc Rosen, Brandon Luber
Publikováno v: Journal of Clinical Oncology. 34:236-236
236 Background: We documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e. BAT) [PMID: 25568070]. Since the adaptive increase in androgen receptor expr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c09c0e5f2619b8147e1d4e029ddb84cd
https://doi.org/10.1200/jco.2016.34.2_suppl.236
Zobrazit plný text záznamu
5
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
Autor: Serina King, Avery Spitz, Ramesh Boinpally, Roberto Pili, Mario A. Eisenberger, Amy Franke, Christopher Sweeney, Michael A. Carducci, Jennifer M. Porter, Lee P. Resta
Publikováno v: Cancer Chemotherapy and Pharmacology
Purpose To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. Methods This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f683f7bdcef003a51ff04c5617448d
https://pubmed.ncbi.nlm.nih.gov/20445979
Zobrazit plný text záznamu
8
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
Autor: Avery Spitz, Sharyn D. Baker, Jing Li, Mats O. Karlsson, Ming Zhao, Julie R. Brahmer, Manuel Hidalgo
Publikováno v: Journal of the National Cancer Institute. 98(23)
Gefitinib is an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) with activity in non-small-cell lung cancer. The response to gefitinib is variable, possibly because of interindividual variation in the activity
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::901ae04992037838a42fe18b5f10147f
https://pubmed.ncbi.nlm.nih.gov/17148773
Zobrazit plný text záznamu
9
A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC)
Autor: Alberto Pacheco, Emmanuel S. Antonarakis, Avery Spitz, Samuel R. Denmeade, Haiyi Cao, Hao Wang, Mario A. Eisenberger, Michael A. Carducci, Michael T. Schweizer
Publikováno v: Journal of Clinical Oncology. 32:5052-5052
45 Background: Prostate cancer (PC) cells become resistant to chronic castration via an adaptive increase in androgen receptor (AR) expression, a liability that can be exploited therapeutically. Mechanistically, supraphysiologic androgens can induce
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67dc9fa61d40004ce7cd246b6f622c25
https://doi.org/10.1200/jco.2014.32.15_suppl.5052
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje